NF2-SWN management primarily relies on serial annual surveillance imaging to track tumor progression and evaluate risks to adjacent critical structures, given the limited effectiveness of pharmacologic, radiation, and surgical treatments. This evidence concerns the gene NF2 and neoplasm.